(Q34324861)

1 August 2017

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy (English)

1 reference

progressive multifocal leukoencephalopathy

1 August 2017

0 references

0 references

1 reference

7

Michael Pawlita

0 references

Tania Kümpfel

8

object named as

Tania Kümpfel

1 reference

1 August 2017

Thomas Weber

15

0 references

Hans-Peter Hartung

18

object named as

Hans-Peter Hartung

1 reference

1 August 2017

23

Bernd C Kieseier

1 reference

1 August 2017

6

Ralf Gold

1 reference

1 August 2017

Christoph Kleinschnitz

17

object named as

Christoph Kleinschnitz

1 reference

1 August 2017

Clemens Warnke

1

1 reference

1 August 2017

Gloria von Geldern

2

1 reference

1 August 2017

Philipp Markwerth

3

1 reference

1 August 2017

Thomas Dehmel

4

1 reference

1 August 2017

Robert Hoepner

5

1 reference

1 August 2017

Mathias Mäurer

9

1 reference

1 August 2017

Martin Stangel

10

1 reference

1 August 2017

Florian Wegner

11

1 reference

1 August 2017

Reinhard Hohlfeld

12

1 reference

1 August 2017

Vera Straeten

13

1 reference

1 August 2017

Volker Limmroth

14

1 reference

1 August 2017

Derik Hermsen

16

1 reference

1 August 2017

Mike P Wattjes

19

1 reference

1 August 2017

Anders Svenningson

20

1 reference

1 August 2017

Eugene Major

21

1 reference

1 August 2017

Tomas Olsson

22

1 reference

1 August 2017

Ortwin Adams

24

1 reference

1 August 2017

8 May 2014

1 reference

1 August 2017

1 reference

1 August 2017

76

1 reference

1 August 2017

6

1 reference

1 August 2017

792-801

1 reference

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Interpretation of positive molecular tests of common viruses in the cerebrospinal fluid

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Changes to anti-JCV antibody levels in a Swedish national MS cohort

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Asymptomatic reactivation of JC virus in patients treated with natalizumab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194179

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies

6 July 2018

1 reference

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

21 January 2018

1 reference

Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

21 January 2018

1 reference

A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology

21 January 2018

1 reference

An assay to quantify species-specific anti-JC virus antibody levels in MS patients

21 January 2018

1 reference

Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid

21 January 2018

1 reference

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

21 January 2018

1 reference

The effect of plasma exchange on serum anti-JC virus antibodies

21 January 2018

1 reference

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

21 January 2018

1 reference

Discrepant findings in immune responses to JC virus in patients receiving natalizumab

21 January 2018

1 reference

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors

21 January 2018

1 reference

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

21 January 2018

1 reference

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

21 January 2018

1 reference

Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response

21 January 2018

1 reference

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

21 January 2018

1 reference

12 December 2020

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS

1 reference

12 December 2020

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

1 reference

12 December 2020

Asymptomatic reactivation of JC virus in patients treated with natalizumab

1 reference

12 December 2020

Identifiers

DOI

10.1002/ANA.24153

1 reference

1 August 2017

1 reference

1 August 2017

1 reference